| Sep 16 |
MRK
|
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 |
| Sep 15 |
MRK
|
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) |
| Sep 15 |
MRK
|
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma |
| Sep 14 |
MRK
|
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report |
| Sep 14 |
MRK
|
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer |
| Sep 14 |
MRK
|
Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers? |
| Sep 14 |
MRK
|
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer |
| Sep 14 |
MRK
|
Merck & Co., Inc. (MRK): A Good Beginner Stock According to Analysts |
| Sep 14 |
MRK
|
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Sep 14 |
MRK
|
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer |
| Sep 14 |
MRK
|
TIGIT drug from iTeos shrinks lung tumors in trial |
| Sep 14 |
MRK
|
Merck Keytruda cuts mortality risk in gastric cancer by 20% |
| Sep 14 |
MRK
|
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma |
| Sep 14 |
MRK
|
Merck Appears Ready To Return To June Highs (Technical Analysis) |
| Sep 13 |
MRK
|
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target |
| Sep 13 |
MRK
|
Summit boosts Instil, BioNTech as lead drug beats Merck’s Keytruda |
| Sep 13 |
MRK
|
Merck goes ex dividend Monday |
| Sep 13 |
MRK
|
Investors in Merck (NYSE:MRK) have seen decent returns of 74% over the past three years |
| Sep 12 |
MRK
|
Moderna cites 2025 launch for Merck partnered cancer vaccine: report |
| Sep 12 |
MRK
|
Moderna Cost Cuts Fail to Restore Investor Trust |
